The basic and applied research of the Institute of Medical Biology of Chinese Academy of Medical Sciences focuses on viral immunology, microbiology, molecular biology, medical genetics, molecular epidemiology, laboratory animal science and other disciplines, and always focuses on the research and development of national vaccines, genetic engineering drugs and diagnostic and therapeutic preparations for major infectious diseases, forming a pattern of basic, application and development.
In the past 50 years, the Institute of Biology has undertaken more than 200 national, provincial, ministerial, international and domestic cooperation projects, and established good cooperative relations with many research institutions and laboratories at home and abroad, and the research in the corresponding fields is at the advanced level at home and abroad. In the past 50 years, the Institute of Biology has won the National Scientific Research Achievement Award 18, 55 provincial and ministerial scientific research achievement awards, 37 academic and municipal scientific research achievements, and one achievement of genetics won the second prize of the National Natural Science Award in 2005. * * * applied for 23 patents, and was granted 1 1; Since its establishment, it has published nearly 2000 papers in academic journals at home and abroad, and more than 50 papers have been included in SCI.
The progress of science and technology is inseparable from the cultivation of talents. In the past 50 years, the development of biological research institute is closely related to the efforts of several generations and the emergence of talents. Always put talent training in an important position in career development, and adhere to multi-level and multi-form training for a long time. It has formed an all-round talent training model consisting of degree education, academic education, continuing education and on-the-job training. In the field of applied basic research, a talent echelon with reasonable structure and discipline distribution has been cultivated, and an innovative talent team with young and middle-aged experts who have made outstanding contributions to the Ministry of Health and a group of young and middle-aged scientific and technological personnel such as doctors and masters have been formed, covering more than 10 related disciplines, providing excellent professional and technical personnel support for biological basic and applied research, pilot and industrial production.
Two, a national new drug-Sabin strain polio inactivated vaccine (single vaccine)
201565438+1October 14. The State Food and Drug Administration of the United States approved the application for the production and registration of the world's first Sabin inactivated polio vaccine (single vaccine). On the afternoon of June 5438+1October 65438+May 5, dozens of central media reporters attended the press conference of the world's first inactivated Sabin polio vaccine independently developed by China in the lecture hall on the fourth floor of Zone D of the Ministry of Science and Technology. It was announced at the meeting:
With the continuous support of national science and technology programs such as "High-tech Research and Development Program (863 Program)" and "Major New Drug Creation", and the support of Bill Melinda Gates Foundation, the Institute of Medical Biology of Chinese Academy of Medical Sciences, after more than 20 years of efforts, independently developed Sabine strain polio inactivated vaccine (hereinafter referred to as "S-IPV") officially obtained the new drug certificate and GMP certification, which indicates that China is in the process of.
The vaccine was developed by Institute of Medical Biology, Chinese Academy of Medical Sciences. Sabin strain was produced by live attenuated polio vaccine, and the virus was harvested in Vero cell bioreactor, combined with the production process of inactivated vaccine. Only a few foreign enterprises use wild strain of polio to produce inactivated polio vaccine, and its products are widely used in developed countries. A company's products are classified as second-class vaccines in China, but the quantity is limited and the price is high. To ensure that China's national commitment to WHO's polio eradication is fulfilled, it is estimated that the annual demand for inactivated polio vaccine will reach tens of millions of doses. As a major innovative product with completely independent intellectual property rights in China, the approved Sabine strain polio inactivated vaccine has successfully achieved the progress from "Made in China" to "Created in China". It not only fills the gap in the production field of inactivated polio vaccine in China, but also breaks the monopoly of the production technology of inactivated polio vaccine in developed countries, which will have a positive impact on the eradication of polio in China and even in the world, especially in developing countries.
The successful research and development of S-IPV has broken the monopoly of developed countries on the production of inactivated polio vaccine. Its approval for marketing fills the gap in the production of inactivated polio vaccine in China.
According to the US Food and Drug Administration, the vaccine will be gradually incorporated into the planned immunization program in China. Recently, WHO also proposed that Sabin inactivated polio vaccine produced in China be included in the global polio eradication action plan.
Three, the national new drug-enterovirus 7 1 inactivated vaccine (human diploid cells)
Since 2008, the Institute of Medical Biology of Chinese Academy of Medical Sciences has started the research and development of EV7 1 inactivated vaccine, which was supported by the Health and Family Planning Commission as a major national science and technology project for new drug creation. On the basis of studying the biological characteristics and infection mechanism of EV7 1, the adaptive passage, immunogenicity, safety and genetic characteristics of EV7 1 in human diploid cells were comprehensively studied from the perspective of virus isolation. In the absence of similar vaccines developed and marketed at home and abroad, this product broke through the key technical bottleneck of large-scale production and quality control of vaccine diploid cells, and established the process system, quality control and quality standard system for large-scale production, laying the foundation for the production of safe, effective and quality-controllable vaccine products. The clinical trial results of tens of thousands of subjects show that the vaccine is safe, and the protection rate of hand, foot and mouth disease caused by EV7 1 can reach 97.3%, which indicates that it can obviously reduce the incidence of hand, foot and mouth disease after marketing and has good clinical benefits.
The advent of the vaccine is of great significance to effectively reduce the incidence of hand, foot and mouth disease in children in China, especially to reduce the number of severe cases and deaths, and to protect the lives and health of children in China.